Diana Stefania Gutierrez

Ms. Diana Stefania Gutierrez

Instituto Nacional de Investigación en Salud Pública, Guayaquil, Guayas, Ecuador

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2022 in Viruses
Verified
Journal Article
Open access
PDF file
Andrés Carrazco-MontalvoAndrés Carrazco-Montalvo
Andrés Carrazco-Montalvo
AHAndrés Herrera-Yela
Andrés Herrera-Yela
DADamaris Irene Alarcón-Vallejo
Damaris Irene Alarcón-Vallejo
DGDiana Stefania Gutierrez
Diana Stefania Gutierrez
Isaac Armendáriz-CastilloIsaac Armendáriz-Castillo
Isaac Armendáriz-Castillo
LPLeandro Patiño
Leandro Patiño
The Omicron variant of SARS-CoV-2 is the latest pandemic lineage causing COVID-19. Despite having a vaccination rate ≥85%, Ecuador recorded a high incidence of Omicron from December 2021 to March 2022. Since Omicron emerged, it has evolved into multiple sub-lineages with distinct prevalence in different regions. In this work, we use all Omicron sequences from Ecuador available at GISAID until March 2022 and the software Nextclade and Pangolin to identify which lineages circulate in this country. We detected 12 different sub-lineages (BA.1, BA.1.1, BA.1.1.1, BA.1.1.14, BA.1.1.2, BA.1.14, BA.1.15, BA.1.16, BA.1.17, BA.1.6, BA.2, BA.2.3), which have been reported in Africa, America, Europe, and Asia, suggesting multiple introduction events. Sub-lineages BA.1 and BA.1.1 were the most prevalent. Genomic surveillance must continue to evaluate the dynamics of current sub-lineages, the early introduction of new ones and vaccine efficacy against evolving SARS-CoV-2.

19 June 2023 in Viruses
Verified
Journal Article
Open access
PDF file
AZAlicia Esperanza Zhingre
Alicia Esperanza Zhingre
CBCésar Bedoya-Pilozo
César Bedoya-Pilozo
DGDiana Stefania Gutierrez
Diana Stefania Gutierrez
IBInés Badano
Inés Badano
AHAndrés Herrera-Yela
Andrés Herrera-Yela
Andrés Carrazco-MontalvoAndrés Carrazco-Montalvo
Andrés Carrazco-Montalvo
Human Papillomavirus (HPV) infection is associated with intraepithelial neoplasia and cervical cancer (CC). Ecuador has a high prevalence of cervical cancer, with more than 1600 new cases diagnosed annually. This study aimed to analyze oncogenes E6 and E7 of HPV16 in samples collected from women with cancerous and precancerous cervical lesions from the Ecuadorian coast. Twenty-nine women, including six with ASCUS, three with LSIL, thirteen with HSIL, and seven with Cacu, were analyzed. The most common SNPs were E6 350G or L83V (82.6%) and E6 145T/286A/289G/335T/350G or Q14H/F78Y/L83V (17.4%). Both variants are reported to be associated with an increased risk of cervical cancer in worldwide studies. In contrast, all E7 genes have conserved amino-acid positions. Phylogenetic trees showed the circulation of the D (26.1%) and A (73.9) lineages. The frequency of D was higher than that reported in other comparable studies in Ecuador and Latin America, and may be related to the ethnic composition of the studied populations. This study contributes to the characterization of the potential risk factors for cervical carcinogenesis associated with Ecuadorian women infected with HPV16.

28 May 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
Andrés Carrazco-MontalvoAndrés Carrazco-Montalvo
Andrés Carrazco-Montalvo
DGDiana Stefania Gutierrez
Diana Stefania Gutierrez
JGJOHANNA VALENTINA AREVALO GRANDA
JOHANNA VALENTINA AREVALO GRANDA
PPPatricio Ponce
Patricio Ponce
CRCristina Jeanneth Rodríguez-Pólit
Cristina Jeanneth Rodríguez-Pólit
VCVarsovia Enid Cevallos
Varsovia Enid Cevallos
Ecuador, a tropical country with frequent dengue outbreaks, including a surge from 16,017 cases in 2022 to 61,329 in 2024, was the focus of this study. The study was conducted in Borbon, a semi-urban rural town in the Esmeraldas province. Genomic analysis, alongside entomo-virological surveillance, provides valuable insights into DENV-2 genotypes. Five pools of female Aedes aegypti mosquitoes from Borbon tested positive for DENV serotype 2 through RT-qPCR. One positive pool (CT = 16.13) was sequenced using Illumina MiSeq, and genotyping was conducted via the Dengue Typing Tool and Maximum Likelihood phylogenetic tree. The genotype assigned was III Southern Asian-American. Comparison with other genomes revealed genetic similarity to a human dengue genome sequenced in 2021, also from Esmeraldas, clustering with genomes reported across the Americas, particularly from Colombia and Venezuela. This study enhances our understanding of dengue virus epidemiology in rural areas, emphasizing the critical role of clinical case surveillance and vector monitoring in guiding evidence-based interventions.

21 April 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
Andrés Carrazco-MontalvoAndrés Carrazco-Montalvo
Andrés Carrazco-Montalvo
AHAndrés Herrera-Yela
Andrés Herrera-Yela
DADamaris Irene Alarcón-Vallejo
Damaris Irene Alarcón-Vallejo
DGDiana Stefania Gutierrez
Diana Stefania Gutierrez
Isaac Armendáriz-CastilloIsaac Armendáriz-Castillo
Isaac Armendáriz-Castillo
LPLeandro Patiño
Leandro Patiño
The Omicron variant of SARS-CoV-2 is the latest pandemic lineage causing COVID-19. Despite having a vaccination rate ≥ 85% Ecuador recorded a high incidence of Omicron from December 2021 to March 2022. Since Omicron emerged it is evolving into multiple sublineages with distinct prevalence in different regions. In this work, we use all Omicron sequences from Ecuador available at GISAID until March 2022 and the software Nextclade and Pangolin to identify which lineages circulate in this country. We detected 12 different sublineages (BA.1, BA.1.1, BA.1.1.1, BA.1.1.14, BA.1.1.2, BA.1.14, BA.1.15, BA.1.16, BA.1.17, BA.1.6, BA.2, BA.2.3), which has been reported in Africa, America, Europe, and Asia suggesting multiple introduction events. Sublineages BA.1.1 and BA.1 were the most prevalent. Genomic surveillance must continue to evaluate the dynamic of current sublineages, early introduction of new ones and vaccine efficacy against evolving SARS-CoV-2.